From the pathogenesis to the cure of indolent B-cell lymphoproliferative disorders associated with hepatitis C virus infection: which role for direct-acting antivirals?

References

• Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553–562.
   PubMed Web of Science ®Google Scholar
• Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14(2):122–132.
   PubMed Web of Science ®Google Scholar
• Ferri C, Ramos-Casals M, Zignego AL, et al. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev. 2016;15(12):1145–1160.
   PubMed Web of Science ®Google Scholar
• De Vita S, Soldano F, Isola M, et al. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis. 2011;70:1183–1190.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Gragnani L, Comarmond C, et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46(Suppl. 5):S165–S173.
   PubMedGoogle Scholar
• Ramos-Casals M, Stone JH, Cid MC, et al. The cryoglobulinaemias. Lancet. 2012;379:348–360.
   PubMed Web of Science ®Google Scholar
• Zignego AL, Ferri C, Pileri SA, et al. Extrahepatic manifestations of hepatitis C virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis. 2007;39:2–17.
   PubMedGoogle Scholar
• Negro F, Forton D, Craxì A, et al. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149:1345–1360.
   PubMed Web of Science ®Google Scholar
• Retamozo S, Díaz-Lagares C, Bosch X, et al. Life-threatening cryoglobulinemic patients with hepatitis C: clinical description and outcome of 279 patients. Medicine (Baltimore). 2013;92(5):273–284.
   PubMed Web of Science ®Google Scholar
• Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood. 2003;102(3):996–999.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Park H, Henry L, et al. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016;150(7):1599–1608.
   PubMed Web of Science ®Google Scholar
• Casato M, Taliani G, Pucillo LP, et al. Cryoglobulinaemia and hepatitis C virus. Lancet. 1991;337(8748):1047–1048.
   PubMed Web of Science ®Google Scholar
• Ferri C, Greco F, Longombardo G, et al. Association between hepatitis C virus and mixed cryoglobulinemia. Clin Exp Rheumatol. 1991;9(6):621–624.
   PubMed Web of Science ®Google Scholar
• Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327(21):1490–1495.
   PubMed Web of Science ®Google Scholar
• Ferri C, Caracciolo F, Zignego AL, et al. Hepatitis C virus infection in patients with non-Hodgkin’s lymphoma. Br J Haematol. 1994;88:392–394.
   PubMed Web of Science ®Google Scholar
• Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2006;15:2078–2085.
   PubMed Web of Science ®Google Scholar
• Monti G, Pioltelli P, Saccardo F, et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med. 2005;165(1):101–105.
   PubMedGoogle Scholar
• Kawamura Y, Ikeda K, Arase Y, et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med. 2007;120(12):1034–1041.
   PubMed Web of Science ®Google Scholar
• Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med. 1994;330(11):751–756.
   PubMed Web of Science ®Google Scholar
• Dammacco F, Sansonno D, Han JH, et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood. 1994;84:3336–3343.
   PubMed Web of Science ®Google Scholar
• Casato M, Agnello V, Pucillo LP, et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood. 1997;90(10):3865–3873.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Resche-Rigon M, Thibault V, et al. P. Antiviral therapy for hepatitis C virus–associated mixed cryoglobulinemia vasculitis: a long-term follow-up study. Arthritis Rheum. 2006;54(11):3696–3706.
   PubMed Web of Science ®Google Scholar
• Mazzaro C, Monti G, Saccardo F, et al. Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study. Clin Exp Rheumatol. 2011;29:933–941.
   PubMed Web of Science ®Google Scholar
• Gragnani L, Fognani E, Piluso A, et al. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. Hepatology. 2015;61:1145–1153.
   PubMed Web of Science ®Google Scholar
• Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med. 2013;369:1035–1045.
   PubMed Web of Science ®Google Scholar
• Peveling-Oberhag J, Arcaini L, Bankov K, et al. The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis. J Viral Hepat. 2016;23(7):536–544.
   PubMed Web of Science ®Google Scholar
• Vannata B, Arcaini L, Zucca E. Hepatitis C virus-associated B-cell non-Hodgkin’s lymphomas: what do we know? Ther Adv Hematol. 2016;7(2):94–107.
   PubMed Web of Science ®Google Scholar
• Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166:637–648.
   PubMed Web of Science ®Google Scholar
• Suarez F, Lortholary O, Hermine O, et al. Infection-associated lymphomas derived from marginal zone B-cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107:3034–3044.
   PubMed Web of Science ®Google Scholar
• Carbonari M, Caprini E, Tedesco T, et al. Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis. J Immunol. 2005;174:6532–6539.
   PubMed Web of Science ®Google Scholar
• Charles ED, Green RM, Marukian S, et al. Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood. 2008;111:1344–1356.
   PubMed Web of Science ®Google Scholar
• Gorevic P, Frangione B. Mixed cryoglobulinemia cross-reactive idiotypes: implications for the relationship of MC to rheumatic and lymphoproliferative diseases. Semin Hematol. 1991;28:79–94.
   PubMed Web of Science ®Google Scholar
• Agnello V, Zhang QX, Abel G, et al. The association of hepatitis C virus infection with monoclonal rheumatoid factors bearing the WA cross-idiotype: implications for the etiopathogenesis and therapy of mixed cryoglobulinemia. Clin Exp Rheumatol. 1995;13(Suppl. 13):S101–S104.
   PubMed Web of Science ®Google Scholar
• Ivanovski M, Silvestri F, Pozzato G, et al. Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood. 1998;91:2433–2442.
   PubMed Web of Science ®Google Scholar
• De Re V, De Vita S, Marzotto A, et al. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus–associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor–producing cells that occur mainly in type II cryoglobulinemia. Blood. 2000;96:3578–3584.
   PubMed Web of Science ®Google Scholar
• Chan CH, Hadlock KG, Foung SK, et al. The VH1–69 gene is preferentially used both by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood. 2001;97:1023–1026.
   PubMed Web of Science ®Google Scholar
• Quinn ER, Chan CH, Hadlock KG, et al. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood. 2001;98(13):3745–3749.
   PubMed Web of Science ®Google Scholar
• Ng P, Kuo C, Wang S, et al. B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins. Blood. 2014;123:1512–1515.
   PubMed Web of Science ®Google Scholar
• De Re V, Sansonno D, Simula MP, et al. HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferations. Leukemia. 2006;20:1145–1154.
   PubMed Web of Science ®Google Scholar
• Zignego AL, Wojcik GL, Cacoub P, et al. Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. Genes Immun. 2014;15(7):500–505.
   PubMed Web of Science ®Google Scholar
• Ito M, Masumi A, Mochida K, et al. Peripheral B cells may serve as a reservoir for persistent hepatitis C virus infection. J Innate Immun. 2010;2:607–617.
   PubMed Web of Science ®Google Scholar
• Marukian S, Jones CT, Andrus L, et al. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology. 2008;48:1843–1850.
   PubMed Web of Science ®Google Scholar
• Stamataki Z1, Shannon-Lowe C, Shaw J, et al. Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Blood. 2009;113:585–593.
   PubMed Web of Science ®Google Scholar
• Machida K, Cheng K, Sung V, et al. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci USA. 2004;101:4262–4267.
   PubMed Web of Science ®Google Scholar
• Rosa D, Saletti G, De Gregorio E, et al. Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci U S A. 2005;102(51):18544–18549.
   PubMed Web of Science ®Google Scholar
• Dai B, Chen AY, Corkum CP, et al. Hepatitis C virus upregulates B-cell receptor signaling: a novel mechanism for HCV-associated B-cell lymphoproliferative disorders. Oncogene. 2016;35(23):2979–2990.
   PubMed Web of Science ®Google Scholar
• Chen CL, Huang JY, Wang CH, et al. Hepatitis C virus has a genetically determined lymphotropism through co-receptor B7.2. Nat Commun. 2017;8:13882. DOI:10.1038/ncomms13882.
   PubMed Web of Science ®Google Scholar
• Weller S, Braun MC, Tan BK, et al. Human blood IgM “memory” B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood. 2004;104:3647–3654.
   PubMed Web of Science ®Google Scholar
• Visentini M, Cagliuso M, Conti V, et al. Clonal B cells of HCV-associated mixed cryoglobulinemia patients contain exhausted marginal zone-like and CD21(low) cells overexpressing Stra13. Eur J Immunol. 2012;42:1468–1476.
   PubMed Web of Science ®Google Scholar
• Charles ED, Brunetti C, Marukian S, et al. Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood. 2011;117:5425–5437.
   PubMed Web of Science ®Google Scholar
• Terrier B, Joly F, Vazquez T, et al. Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity. J Immunol. 2011;187:6550–6563.
   PubMed Web of Science ®Google Scholar
• Moir S, Ho J, Malaspina A, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med. 2008;205:1797–1805.
   PubMed Web of Science ®Google Scholar
• Rakhmanov M, Keller B, Gutenberger S, et al. Circulating CD21low B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells. Proc Natl Acad Sci USA. 2009;106:13451–13456.
   PubMed Web of Science ®Google Scholar
• Visentini M, Cagliuso M, Conti V, et al. Telomere-dependent replicative senescence of B and T cells from patients with type 1a common variable immunodeficiency. Eur J Immunol. 2011;41:854–862.
   PubMed Web of Science ®Google Scholar
• McMahan RH, Golden-Mason L, Nishimura MI, et al. Tim-3 expression on PD-1- HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest. 2010;120:4546–4557.
   PubMed Web of Science ®Google Scholar
• Shin EC, Park SH, Nascimbeni M, et al. The frequency of CD127(+) hepatitis C virus (HCV)-specific T cells but not the expression of exhaustion markers predicts the outcome of acute HCV infection. J Virol. 2013;87:4772–4777.
   PubMed Web of Science ®Google Scholar
• Visentini M, Conti V, Cristofoletti C, et al. Clonal expansion and functional exhaustion of monoclonal marginal zone B cells in mixed cryoglobulinemia: the yin and yang of HCV-driven lymphoproliferation and autoimmunity. Autoimmun Rev. 2013;12(3):430–435.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Vallisa D, Rattotti S, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol. 2014;25:1404–1410.
   PubMed Web of Science ®Google Scholar
• De Re V, De Vita S, Marzotto A, et al. Pre-malignant and malignant lymphoproliferations in an HCV-infected type II mixed cryoglobulinemic patient are sequential phases of an antigen-driven pathological process. Int J Cancer. 2000;87(2):211–216.
   PubMed Web of Science ®Google Scholar
• Matteucci C, Bracci M, Barba G, et al. Different genomic imbalances in low- and high-grade HCV-related lymphomas. Leukemia. 2008;22:219–222.
   PubMed Web of Science ®Google Scholar
• Kasama Y, Sekiguchi S, Saito M, et al. Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo. Blood. 2010;116(23):4926–4933.
   PubMed Web of Science ®Google Scholar
• Machida K, Liu J, Mcnamara G, et al. Hepatitis C virus causes uncoupling of mitotic checkpoint and chromosomal polyploidy through the Rb pathway. J Virol. 2009;83:12590–12600.
   PubMed Web of Science ®Google Scholar
• Machida K, Tsukiyama-Kohara K, Sekiguch S, et al. Hepatitis C virus and disrupted interferon signaling promote lymphoproliferation via type II CD95 and interleukins. Gastroenterology. 2009;137:285–296.
   PubMed Web of Science ®Google Scholar
• Peveling-Oberhag J, Crisman G, Schmidt A, et al. Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection. Leukemia. 2012;26:1654–1662.
   PubMed Web of Science ®Google Scholar
• Fognani E, Giannini C, Piluso A, et al. Role of microRNA profile modifications in hepatitis C virus-related mixed cryoglobulinemia. PLoS One. 2013;8:e62965.
   PubMed Web of Science ®Google Scholar
• Augello C, Gianelli U, Savi F, et al. MicroRNA as potential biomarker in HCV-associated diffuse large B-cell lymphoma. J Clin Pathol. 2014;67:697–701.
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the international lymphoma epidemiology consortium. Clin Gastroenterol Hepatol. 2008;6:451–458.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Suarez F, Lefrere F, et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood. 2005;105:74–76.
   PubMed Web of Science ®Google Scholar
• Paulli M, Arcaini L, Lucioni M, et al. Subcutaneous ‘lipoma-like’ B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. Ann Oncol. 2010;21:1189–1195.
   PubMed Web of Science ®Google Scholar
• Bonomo L, Casato M, Afeltra A, et al. Treatment of idiopathic mixed cryoglobulinemia with alpha interferon. Am J Med. 1987;83:726–730.
   PubMed Web of Science ®Google Scholar
• Casato M, Lagana B, Antonelli G, et al. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood. 1991;78:314–318.
   Web of Science ®Google Scholar
• Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-∥/ribavirin compared with Peg-interferon-α∥/ribavirin in hepatitis C–related mixed cryoglobulinemia. Blood. 2010;116(3):326–334.
   PubMed Web of Science ®Google Scholar
• Dammacco F, Tucci FA, Lauletta F, et al. Pegylated interferon-∥α, ribavirin, and rituximab combined therapy of hepatitis C virus–related mixed cryoglobulinemia: a long-term study. Blood. 2010;116(3):343–353.
   PubMed Web of Science ®Google Scholar
• Landau DA, Saadoun D, Halfon P, et al. Relapse of hepatitis C virus–associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum. 2008;58(2):604–611.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Zignego AL, Ferri C, et al. Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. J Hepatol. 2017Feb17;66:1282–1299. pii: S0168-8278(17)30105-8. 10.1016/j.jhep.2017.02.010.
   PubMed Web of Science ®Google Scholar
• Zignego AL, Ramos-Casals M, Ferri C, et al. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmun Rev. 2017;16(5):523–541.
   PubMed Web of Science ®Google Scholar
• Bauduer F. MALT non-Hodgkin’s lymphoma associated with hepatitis C virus infection treated by interferon alpha. Am J Hematol. 1996;53:209.
   PubMed Web of Science ®Google Scholar
• Patriarca F, Silvestri F, Fanin R, et al. Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment. Br J Haematol. 2001;112:370–372.
   PubMed Web of Science ®Google Scholar
• Casato M, Mecucci C, Agnello V, et al. Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia. Blood. 2002;99(6):2259–2261.
   PubMed Web of Science ®Google Scholar
• Hermine O, Lefrère F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347(2):89–94.
   PubMed Web of Science ®Google Scholar
• Pitini V, Arrigo C, Righi M, et al. Systematic screening for HCV infection should be performed in patients with splenic marginal zone lymphoma. Br J Haematol. 2004;124:252–253.
   PubMed Web of Science ®Google Scholar
• Kelaidi C, Rollot F, Park S, et al. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia. 2004;18:1711–1716.
   PubMed Web of Science ®Google Scholar
• Tursi A, Brandimarte G, Torello M. Disappearance of gastric mucosa- associated lymphoid tissue in hepatitis C virus-positive patients after anti- hepatitis C virus therapy. J Clin Gastroenterol. 2004;38:360–363.
   PubMed Web of Science ®Google Scholar
• Svoboda J, Andreadis C, Downs LH, et al. Regression of advanced non-splenic marginal zone lymphoma after treatment of hepatitis C virus infection. Leuk Lymphoma. 2005;46:1365–1368.
   PubMed Web of Science ®Google Scholar
• Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: a multicenter Italian experience. J Clin Oncol. 2005;23:468–473.
   PubMed Web of Science ®Google Scholar
• Mazzaro C, De Re V, Spina M, et al. Pegylated-interferon plus ribavirin for HCV positive indolent non-Hodgkin lymphomas. Br J Haematol. 2009;145:255.257.
   PubMed Web of Science ®Google Scholar
• Oda Y, Kou T, Watanabe M, et al. Regression of B-cell lymphoma of the liver with hepatitis C virus infection after treatment with pegylated interferon-alpha and ribavirin. Dig Dis Sci. 2010;55:1791–1793.
   PubMed Web of Science ®Google Scholar
• Pellicelli AM, Marignani M, Zoli V, et al. Hepatitis C virus-related B cell subtypes in non Hodgkin’s lymphoma. World J Hepatol. 2011;3:278–284.
   PubMedGoogle Scholar
• Mauro E, Pedata M, Ermacora A, et al. An additional line of therapy with pegylated interferon and ribavirin after rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia and indolent non-Hodgkin’s lymphoma previously treated with interferon. Blood Transfus. 2012;10:101–103.
   PubMed Web of Science ®Google Scholar
• Michot JM, Canioni D, Driss H, et al. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol. 2015;90(3):197–203.
   PubMed Web of Science ®Google Scholar
• Gragnani L, Visentini M, Fognani E, et al. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology. 2016;64(5):1473–1482.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Thibault V, Si Ahmed SN, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2016;75(10):1777–1782.
   PubMed Web of Science ®Google Scholar
• Bonacci M, Lens S, Londoño MC, et al. Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting antivirals. Clin Gastroenterol Hepatol. 2017;15(4):575–583.
   PubMed Web of Science ®Google Scholar
• Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63(2):408–417.
   PubMed Web of Science ®Google Scholar
• Sollima S, Milazzo L, Peri AM, et al. Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy. Rheumatology (Oxford). 2016;55(11):2084–2085.
   PubMed Web of Science ®Google Scholar
• Artemova M, Abdurakhmanov D, Ignatova T, et al. Persistent hepatitis C virus-associated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapy. Hepatology. 2017;65(5):1770–1771.
   PubMed Web of Science ®Google Scholar
• Zignego AL, Gragnani L, Visentini M, et al. The possible persistence of mixed cryoglobulinemia stigmata in spite of viral eradication: insufficient or too late antiviral treatment? Hepatology. 2017;65(5):1771–1772.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Besson C, Frigeni M, et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood. 2016 Nov 24;128(21):2527–2532.
   PubMed Web of Science ®Google Scholar
• Lim LY, La D, Cserti-Gazdewich CM, et al. Lymphoma remission by interferon-free HCV eradication without chemotherapy. ACG Case Rep J. 2015;3(1):69–70.
   PubMed Web of Science ®Google Scholar
• Andrade P, Príncipe F, Macedo G. Remission of marginal zone lymphoma after HCV eradication with new direct antiviral agents. J Clin Gastroenterol. 2016 Sep 28. Epub ahead of print
   PubMedGoogle Scholar
• de Clerck F, Geerts A, Brochez L, et al. Successful treatment of HCV-associated B-cell non-Hodgkin lymphomas with direct-acting antiviral agents. J Clin Gastroenterol. 2016;50:438.
   PubMed Web of Science ®Google Scholar
• Lin RJ, Moskovits T, Diefenbach CS, et al. Development of highly aggressive mantle cell lymphoma after sofosbuvir treatment of hepatitis C. Blood Cancer J. 2016;6:e402.
   PubMed Web of Science ®Google Scholar
• Reig M, Marino Z, Perello C, et al. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol. 2016;65:719–726.
   PubMed Web of Science ®Google Scholar
• Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727–733.
   PubMed Web of Science ®Google Scholar
• Del Padre M, Todi L, Mitrevski M, et al. Reversion of anergy signatures in clonal CD21low B cells of mixed cryoglobulinemia after clearance of HCV viremia. Blood. 2017 May 15. DOI:10.1182/blood-2017-03-771238.
   PubMed Web of Science ®Google Scholar